Evidence map›Paper›PMID 33724653›Full record

SynthesisMolecular oncology2021

Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges.

José Garcia-Pelaez, Rita Barbosa-Matos, Irene Gullo, Fátima Carneiro, Carla Oliveira

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Molecular profile of poorly cohesive gastric carcinoma with special reference to survival.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
  17. Article
  18. Review
  19. Review
  20. A standardized pathology report for gastric cancer: 2nd edition.Journal of pathology and translational medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

José Garcia-Pelaezi3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal.ORCID 0000-0003-0677-8908
Rita Barbosa-Matosi3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal.ORCID 0000-0003-0794-4912
Irene Gulloi3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal.ORCID 0000-0003-3377-0530
Fátima Carneiroi3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal.ORCID 0000-0002-1964-1006
Carla Oliveirai3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Portugal.ORCID 0000-0001-8340-2264

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) pathogenesis is complex and heterogeneous, reflecting morphological, molecular and genetic diversity. Diffuse gastric cancer (DGC) and intestinal gastric cancer (IGC) are the major histological types. GC may be sporadic or hereditary; sporadic GC is related to environmental and genetic low-risk factors and hereditary GC is caused by inherited high-risk mutations, so far identified only for the diffuse histotype. DGC phenotypic heterogeneity challenges the current understanding of molecular mechanisms underlying carcinogenesis. The definition of a DGC-specific mutational profile remains controversial, possibly reflecting the heterogeneity of DGC-related histological subtypes [signet-ring cell carcinoma (SRCC) and poorly cohesive carcinoma not otherwise specified (PCC-NOS)]. Indeed, DGC and DGC-related subtypes may present specific mutational profiles underlying the particularly aggressive behaviour and dismal prognosis of DGC vs IGC and PCC-NOS vs SRCC. In this systematic review, we revised the histological presentations, molecular classifications and approved therapies for gastric cancer, with a focus on DGC. We then analysed results from the most relevant studies, reporting mutational analysis data specifying mutational frequencies, and their relationship with DGC and IGC histological types, and with specific DGC subtypes (SRCC and PCC-NOS). We aimed at identifying histology-associated mutational profiles with an emphasis in DGC and its subtypes (DGC vs IGC; sporadic vs hereditary DGC; and SRCC vs PCC-NOS). We further used these mutational profiles to identify the most commonly affected molecular pathways and biological functions, and explored the clinical trials directed specifically to patients with DGC. This systematic analysis is expected to expose a DGC-specific molecular profile and shed light into potential targets for therapeutic intervention, which are currently missing.

Indexed as

AdenocarcinomaCarcinoma, Signet Ring CellStomach NeoplasmsGerm-Line MutationHumansdiffuse gastric cancerdriver genesintestinal gastric cancermolecular classificationpoorly cohesive carcinomassignet-ring cell carcinoma

Identifiers

PMID33724653
PMCPMC8564639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.